News and Trends 23 May 2017
German Biotech Tops Up its Oncolytic Virus with Immuno-Oncology Drugs
Oryx has reported good clinical data on the combination of its oncolytic virus with immuno-oncology drugs, convincing the biotech to start clinical trials. Based in Munich, Oryx is developing cancer immunotherapies for a number of solid tumors consisting of oncolytic viruses and peptide vaccines. The company just announced positive clinical data for 16 patients treated under compassionate use […]